InsidersTradesSigma
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Discover the full record of transactions filed by Bolte Axel, Chairman & CEO. Director active across 2 companies, notably Inozyme Pharma, Inc.. Cumulatively, 9 filings have been logged. Split: 1 buy · 0 sell. Total volume traded: €232k. History available since 24 June 2021. The latest transaction was disclosed on 1 July 2025 (U). Regulator: SEC (Form 4). The full history is free.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
9 of 9 declarations
Bolte Axel is Président-Directeur Général and has filed 9 forms in total. Across the 9 recent filings available, purchases total EUR 231598, sales are zero, and the period covered runs from 2021-06-25 to 2025-07-03. The most frequent transaction nature is Levée d'options.